Skip to main content

Table 2 Rheumatic symptoms pain intensity, relapse frequency and duration, reported by recovered and affected patients (n = 169)

From: The clinical manifestation and the influence of age and comorbidities on long-term chikungunya disease and health-related quality of life: a 60-month prospective cohort study in Curaçao

 

Recovered (n = 107)

Affecteda (n = 62)

P-valueb

 

n (%)

n (%)

 

Pain intensity (VAS score)

 

 < .001

None

79 (73.8)

0 (0.0)

 

Mild (1–3)

13 (12.1)

11 (17.7)

 

Moderate (4–6)

6 (5.5)

30 (48.4)

 

Severe (7–10)

9 (8.4)

21 (33.9)

 

Relapse frequencyc

  

 < .001

None

96 (89.7)

1 (1.6)

 

1–10

10 (9.3)

33 (53.2)

 

10–20

0 (0.0)

5 (8.1)

 

 > 20

1 (0.9)

23 (37.1)

 

Duration relapsesd

  

.68

1–6 days

9 (81.8)

48 (78.7)

 

7–14 days

1 (9.1)

10 (16.4)

 

15–21 days

0 (0.0)

1 (1.6)

 

 > 22 days

1 (9.1)

2 (3.3)

 
  1. aTotal affected patients with recurrent symptoms n = 62; bGroups were compared using the Fisher’s exact test, with Bonferroni multiple post hoc analysis, two-sided P-value corresponds to the comparison of the proportions of pain intensity, recurrent symptoms frequency and relapse duration (between first follow-up and second follow-up surveys, 30 and 60 months after disease onset), between the recovered and affected groups; cSymptoms relapse frequency among recovered and affected patients, experiencing self-reported chikungunya related recurrent symptoms; dRelapse duration of symptom among recovered and affected patients, experiencing self-reported chikungunya related recurrent symptoms. VAS = Visual Analogue Scale. Significant P-values after Bonferroni correction are indicated in bold
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us